Notice: Get a jump on 2015 — Pay your 2015 ASA membership dues now!

>

MEETINGS / EVENTS

RSS

January 23 - 25 2015, 12:00 AM - 12:00 AM

ASA PRACTICE MANAGEMENT 2015

February 07 - 08 2015, 12:00 AM - 12:00 AM

ASA Certificate in Business Administration 2015

June 26 - 28 2015, 12:00 AM - 12:00 AM

Annual Perioperative Surgical Home Summit

>

FDA MEDWATCH ALERTS

December 18, 2014

0.9 Percent Sodium Chloride Injection USP in 100 mL MINI-BAG PLUS Container by Baxter: Recall - Particulate Matter

Summary:

FDA MedWatch Recall - Particulate Matter

November 21, 2014

FDA MedWatch - Respironics California, Esprit V1000 and V200 Ventilators: Class I Recall - Power Failure May Occur

Summary:

FDA MedWatch Respironics California Esprit V1000 and V200 Ventilators Class I Recall

November 21, 2014

FDA MedWatch - Highly Concentrated Potassium Chloride Injection, 10 mEq per 100 mL by Baxter: Recall - Mislabeled

Summary:

Highly Concentrated Potassium Chloride Injection 10 mEq per 100 mL by Baxter Recall Mislabeled

>

ASA FEATURED PRODUCT

Add this product to your shopping cart

Self-Education and Evaluation (SEE) Program

SKU: 30701-14CE

... Read more »

Single Copies, Member Price: $360

ASA Offers Recommendations to FDA on Opioid Conversion Labeling

Tuesday, August 20, 2013

In formal comments to the Food and Drug Administration (FDA), ASA addressed public health concerns associated with the use of equianalgesic opioid conversion tables and recommended a staged approach for opioid conversion labeling.  This letter follows a July 29 FDA public workshop where ASA representative, Robert Hurley, M.D., Ph.D., a member of ASA’s Committee on Pain Medicine, testified on how to improve how opioids are converted in clinical practice

In the letter, ASA explained that "opioid conversion recommendations must balance the risk of over-dosing with the risk of under-dosing.  However, any recommendations should accept initial short-term under-treatment of pain and subsequent upward dose titration.  Opioid conversion must emphasize the goal of safety by specifying the potential for dose adjustments after calculation of the equianalgesic dose." Given these principles, ASA offered a staged approach for opioid conversion labeling.

ASA will continue working with the FDA on this important issue.  Visit our pain medicine advocacy webpage to learn more about ASA's advocacy on behalf of our members who practice pain medicine.

Read ASA's comment letter.

« Back to Washington Alerts